Martha Flores
Acute Care · El Paso, TXNPI 1194460014
Payments from drug & device makers
Across 109 payments — averaging $30.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$922
- GSK$659
- Pulmonx Corporation$286
- Sanofi$257
- Grifols USA, LLC$248
- Boehringer Ingelheim$235
- plus $711 from 11 others
What the payments were for
- Food & beverage$3,24298%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $922 |
| GSK | 18 | $659 |
| Pulmonx Corporation | 3 | $286 |
| Sanofi | 14 | $257 |
| Grifols USA, LLC | 13 | $248 |
| Boehringer Ingelheim | 8 | $235 |
| Mylan Specialty L.p. | 3 | $145 |
| Mallinckrodt Hospital Products Inc. | 2 | $139 |
| Viatris Specialty LLC | 4 | $89 |
| Novartis | 4 | $77 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| AbbVie | 1 | $24 |
| Biogen | 1 | $23 |
| Amgen | 1 | $18 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CHARTIS CATHETER$277
- ZEPHYR DELIVERY CATHETER$277
- ZEPHYR ENDOBRONCHIAL VALVE$277
- PULMONX CHARTIS TABLET CONSOLE$277
- NUCALA$250
- BREZTRI$204
- ACTHAR$122
- TEZSPIRE$103
- AIRSUPRA$103
- FASENRA$103
How this compares
$3,317 in reported general payments places this provider in the 90th percentile of 2,323 acute care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $34,159 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,571 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $2,502 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,676 |
| Fluticasone Propionate | 19 | $272 |
| Prednisone | 36 | $165 |
| Azithromycin | 11 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $659 | $34,15930 claims |
| AstraZenecaSymbicort | $922 | $5,57113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,323 acute care providers in Texas.
Other acute care in El Paso
- Laura WilsonEl Paso$32K
- Ahtesham AliEl Paso$14K
- Adriana SanchezEl Paso$11K
- Haydee BirkhimerEl Paso$10K
- Patricia DandEl Paso$9K
- Dora CarcobaEl Paso$8K
- Jennifer PilotteDallas$232K
- Christie MorrisonSan Antonio$225K
- Amanda BradleyDallas$85K
- Kim HuynhCypress$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.